Innovation in Drug Research and Development for Prevalent Chronic Diseases

Examines the steps involved in developing treatments for cancer. The recommendations in this book are offered to organisations such as the National Cancer Institute and the pharmaceutical and biotechnology industries and others, who bear responsibility and wield influence in directing the tools for cancer drug development.

---

Investment and innovation in drug research and development (R&D) for highly prevalent chronic diseases has stalled in recent decades, despite half of all Americans living with at least one chronic disease. As a result, prevalent chronic diseases are producing immense health care costs as well as preventable suffering and death. On February 22, March 2, and March 8, 2021, the National Academies of Sciences, Engineering, and Medicine, convened a workshop to discuss barriers to innovation in this space and examine strategies and incentives to support equitable, person-centered drug R&D for prevalent chronic diseases.

Table of Contents


Front Matter
1 Introduction
2 Person-Centered Drug Research and Development
3 New Technologies to Enable Research in Prevalent Chronic Disease
4 Investment and Incentives
5 Learning from Success
6 Lessons Learned for the Future
7 Reflections and Final Thoughts
Appendix A: Workshop Agenda
Appendix B: Biographical Sketches of Workshop Speakers